Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Polliack, A.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(3)
+
-
Availability
Open access
(1)
+
-
Metadata Only
(2)
+
-
Creation Date
2017
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(3)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(3)
+
-
Topic
CLL
(2)
+
-
chemo-immunotherapy
(2)
+
-
Author
Kimby, E.
(3)
+
-
Kozak, T.
(3)
+
-
Polliack, A.
(3)
+
-
Walewski, J.
(3)
+
-
Wittebol, S.
(3)
+
-
Wu, K.L.
(3)
+
-
Abrahamse-Testroote, M.C.J.
(2)
+
-
Alemayehu, W.G.
(2)
+
-
Doorduijn, J.K.
(2)
+
-
Geisler, C.H.
(2)
+
-
Itala-Remes, M.
(2)
+
-
Oers, M.H.J. van
(2)
+
-
Tjonnfjord, G.E.
(2)
+
-
Vojdeman, F.J.
(2)
+
-
Show more
Language
en
(3)
+
-
Search results
(1 - 3 of 3)
show grid
show list
save search
Vojdeman, F.J.; van't Veer, M.B.; Tjonnfjord, G.E.; Itala-Remes, M.; Kimby, E.; Polliack, A.; ... ; Geisler, C.H.
2017
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia
Article / Letter to editor
metadata only
Vojdeman, F.J.; Herman, S.E.M.; Kirkby, N.; Wiestner, A.; t' Veer, M.B. van; Tjonnfjord, G.E.; ... ; Niemann, C.U.
2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
Article / Letter to editor
open access
Vojdeman, F.; van't Veer, M.; Tjonnfjord, G.; Itala-Remes, M.; Kimby, E.; Polliack, A.; ... ; Geisler, C.
2016
PERFORMANCE STATUS AND COMORBIDITY AFFECT SURVIVAL IN ELDERLY PATIENTS WITH CLL AFTER LOW DOSE ALEMTUZUMAB COMBINED WITH CHEMOTHERAPY: RESULTS FROM THE HOVON68 TRIAL
Article / Letter to editor
metadata only
